Neurogene
Update in progressNGNE (NasdaqGM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Neurogene Inc. is a clinical-stage biotechnology company focused on genetic medicines for rare neurological diseases. Its candidates include NGN-401, an AAV9-delivered therapy in Phase 1/2 for Rett syndrome, and NGN-101, a conventional gene therapy in Phase 1/2 for CLN5 Batten disease. The company has licenses with University of Edinburgh, Virovek, Sigma-Aldrich, and Stanford. Founded in 2018, headquartered in New York, NY.
Company score
- Sentiment
- -0.02
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- -0.15
- Governance
- -0.19
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- -0.08
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- -0.05
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqGM (NGM)
- LocationUnited States
- CEODr. Rachel L. McMinn Ph.D.
- Founded2018
- Employees131
- Websitewww.neurogene.com
Identifiers
- ISINUS64135M1053
- FIGIBBG005Y0QDK1
- CUSIP64135M105
- CIK0001404644